![]() |
市場調查報告書
商品編碼
1500499
動物疫苗市場:按動物類型、技術、給藥途徑、分銷管道分類 - 全球預測 2024-2030Veterinary Vaccines Market by Animal Type (Aquaculture, Companion Animals, Livestock), Technology (Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines), Route of Administration, Distribution Channel - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年動物疫苗市場規模為98.2億美元,預計2024年將達104億美元,2030年將達151.9億美元,複合年成長率為6.43%。
獸用疫苗是生物製備的物質,可以刺激動物的免疫系統並保護其免受某些疾病的侵害。這些疫苗的功能與人類疫苗類似,是將抗原(通常是去活化或減毒的病原體或其成分)引入動物體內。這種暴露會引發免疫反應,包括產生抗體、記憶細胞和其他防禦機制,使動物能夠對目標疾病產生免疫力而不會生病。寵物數量的增加、牲畜數量的增加、通用感染疾病意識的增強、動物疾病的快速增加以及動物健康投資的增加正在推動進一步的成長。但由於疫苗儲存成本高、運輸過程中難以維持疫苗活力,擴大市場有重大問題。由於寵物主人數量的增加和生物技術研究的進步,人們對食品安全的興趣日益濃厚,正在市場上創造巨大的商機。
主要市場統計 | |
---|---|
基準年[2023] | 98.2億美元 |
預測年份 [2024] | 104億美元 |
預測年份 [2030] | 151.9億美元 |
複合年成長率(%) | 6.43% |
區域洞察
美洲的獸用疫苗採用率最高,主要是因為動物數量眾多以及動物健康意識的增加。當地動物衛生機構制定的各種法規和指南極大地推動了疫苗的採用。在歐洲、中東和非洲地區,歐洲在獸用疫苗的採用方面處於領先地位,該地區先進的醫療和技術基礎設施、強力的法律規範以及促進動物福利的舉措對這一成長做出了重大貢獻。隨著旨在改善獸醫衛生系統的投資和努力的增加,中東和非洲正在顯示出成長潛力。亞太地區畜牧業人口較多,寵物擁有率較高,獸用疫苗普及潛力大。快速的都市化和寵物擁有的增加,以及政府關於疾病預防的指令,正在推動市場擴張。在亞太地區國家,由於伴同性動物的飼養和認知的提高,都市區的疫苗接種普及不斷提高,人們對動物健康的興趣日益濃厚。
FPNV定位矩陣
FPNV 定位矩陣對於評估獸用疫苗市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對獸用疫苗市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該領域競爭性質的寶貴見解,包括累積研究期、片段化優勢和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在動物疫苗市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[196 Pages Report] The Veterinary Vaccines Market size was estimated at USD 9.82 billion in 2023 and expected to reach USD 10.40 billion in 2024, at a CAGR 6.43% to reach USD 15.19 billion by 2030.
Veterinary vaccines are biologically prepared substances that stimulate an animal's immune system to protect it from specific diseases. These vaccines function similarly to human vaccines by introducing antigens, typically inactivated or attenuated forms of pathogens or their components, into the animal's body. This exposure triggers an immune response, including producing antibodies, memory cells, and other defense mechanisms, so the animal can develop immunity to the targeted disease without getting sick. Increasing pet adoption, livestock population, rising awareness of zoonotic diseases, surging incidences of animal diseases, and escalating investments in animal health drive further growth. However, the high cost of vaccine storage and difficulties in maintaining the viability of vaccines during transport pose significant issues in the market expansion. The increasing count of in-house pets escalated the focus on food safety, and advancements in biotechnological research provide significant opportunities in the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 9.82 billion |
Estimated Year [2024] | USD 10.40 billion |
Forecast Year [2030] | USD 15.19 billion |
CAGR (%) | 6.43% |
Regional Insights
The Americas exhibits the highest adoption of veterinary vaccines, primarily due to the high animal population and increasing awareness of animal health. Various regulations and guidelines set by local animal health organizations have substantially driven vaccine adoption. In EMEA, Europe leads in adopting veterinary vaccines owing to the region's advanced medical and technological infrastructure, robust regulatory frameworks, and initiatives promoting animal welfare, significantly contributing to this growth. In the Middle East and Africa, increasing investments and efforts towards improving animal health care systems signify growth potential. APAC, home to a large livestock population and high pet ownership, presents significant potential for veterinary vaccine adoption. Rapid urbanization and increasing pet adoption rates facilitate market expansion alongside governmental directives on disease prevention. The APAC Countries have been increasingly focusing on animal health as urban areas report high vaccine adoption due to increasing companion animal ownership and awareness.
Market Insights
The market dynamics represent an ever-changing landscape of the Veterinary Vaccines Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Veterinary Vaccines Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Veterinary Vaccines Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Merck Animal Health launches 3-in-one swine vaccine
Merck introduced an innovative three-in-one vaccine, Circumvent CML, for Veterinary Vaccines. This groundbreaking vaccine effectively controls Porcine Circovirus Type 2a and 2d, Mycoplasma hyopneumoniae, and Lawsonia intracellularis diseases. It offers the added convenience of reduced volume in a single-dose administration, making it easier for producers to administer. [Published On: 2023-06-14]
IIL to set up new animal vaccine unit in Hyderabad, India at INR 700 crore
Indian Immunologicals Ltd (IIL) is making a substantial investment of INR 700 crore to establish a state-of-the-art veterinary vaccine manufacturing facility in Hyderabad's Genome Valley. This greenfield facility focuses on producing vaccines for animal conditions such as foot and mouth disease and other emerging diseases. Once operational, the manufacturing plant will significantly increase IIL's FMD vaccine capacity from 300 million doses per annum to an impressive 600 million doses per annum. [Published On: 2022-10-11]
Merck Animal Health to Acquire Venc
Merck Animal Health has recently announced the signing of a definitive agreement to acquire Vence, developed virtual fencing for livestock management and rotational grazing in the context of veterinary vaccines. Vence's virtual fencing technology offers numerous benefits, including reducing the need for physical fencing and labor. It enables producers and ranchers to efficiently manage cattle movement and facilitate rotational grazing, all from the convenience of a computer or smartphone. [Published On: 2022-09-22]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Veterinary Vaccines Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Veterinary Vaccines Market, highlighting leading vendors and their innovative profiles. These include Addison Biological Laboratory Inc., Aptimmune Biologics, Inc, Bimeda Inc., Biokema SA, Boehringer Ingelheim International GmbH, Brilliant Bio Pharma Private Limited, Ceva Sante Animale, China Animal Husbandry Industry Co., Ltd, Covetrus, Inc., Elanco Animal Health Incorporated, Endovac Animal Health., Hester Biosciences Limited, HIPRA, S.A, Indian Immunologicals Ltd., Kemin Industries, Inc., Kyoritsuseiyaku Corporation, Laboratoire LCV, Meiji Holdings Co., Ltd., Merck & Co., Inc, Neogen Corporation, Norbrook Laboratories Limited, Phibro Animal Health Corporation, Saiba Animal Health AG, Sumitomo Pharma Animal Health Co., Ltd., Torigen Pharmaceuticals Inc., Vaxxinova International BV, Virbac SA, YEBIO BIOENGINEERING CO., LTD OF QINGDAO, and Zoetis Inc..
Market Segmentation & Coverage